Group 1 - The core viewpoint of the article highlights that Hengan International's stock has increased by over 3%, reaching HKD 25, with a trading volume of HKD 135 million [1] - For the six months ending June 30, 2025, Hengan International reported a revenue of RMB 11.808 billion, a slight decrease of 0.2% year-on-year [1] - The profit attributable to equity holders was RMB 1.373 billion, reflecting a year-on-year decrease of 2.6% [1] Group 2 - The company maintained an interim dividend of RMB 0.7 per share [1] - Hengan International expects steady growth in tissue sales in the second half of 2025, which will support overall revenue [1] - The company anticipates stable revenue due to strategies focused on multi-channel sales, product personalization, and stable pricing [1] Group 3 - In the second half of 2025, Hengan International plans to increase marketing resource allocation, expecting a positive impact on sales [1] - High-end, high-margin products are projected to continue stable growth [1] - The company expects gross margins to remain stable, assuming raw material prices remain steady [1]

Group 1 - The core viewpoint of the article highlights that Hengan International's stock has risen over 3% following the release of its interim results, indicating positive market sentiment despite a slight decline in revenue and profit [1] - For the six months ending June 30, 2025, Hengan International reported revenue of 11.808 billion RMB, a year-on-year decrease of 0.2%, and a profit attributable to equity holders of 1.373 billion RMB, down 2.6% year-on-year [1] - The company maintained an interim dividend of 0.7 RMB per share, reflecting a commitment to returning value to shareholders despite the slight decline in profits [1] Group 2 - Hengan International expects steady growth in tissue sales in the second half of 2025, which will support overall revenue stability [1] - The company anticipates that its strategies in omni-channel sales, product personalization, and stable pricing will contribute to maintaining revenue stability [1] - Hengan plans to increase marketing resource allocation in the second half of 2025, with expectations for high-end, high-margin products to continue stable growth, supported by stable raw material prices [1]

Core Viewpoint - The company reported a slight decline in revenue and profit for the first half of 2025, but anticipates stable income growth driven by tissue sales and a diversified sales strategy [1][2] Group 1: Financial Performance - The company achieved revenue of 11.808 billion RMB, a year-on-year decrease of 0.2% [1] - Profit attributable to equity holders was 1.373 billion RMB, down 2.6% year-on-year, with basic earnings per share at 1.206 RMB [1] - Overall gross profit decreased by approximately 3.2% to about 3.812 billion RMB, with a gross margin of about 32.3%, down from 33.3% in the same period last year [2] Group 2: Sales and Market Strategy - The company benefited from growth in tissue sales and an increase in market share, mitigating the negative impact of intense price competition in the sanitary products industry [1] - E-commerce and new retail sales accounted for approximately 34.4% of total sales, up from 31.8% in the first half of 2024, with a year-on-year sales revenue growth of about 7.9% [1] - The company is focusing on diversifying sales channels and enhancing its e-commerce presence while also promoting traditional sales channels [1] Group 3: Product Development and Market Trends - The company is actively developing new technologies to enhance product high-end positioning and diversify its product portfolio, responding to the increasing demand for personalized and value-added sanitary products [2] - Key high-end products include the "Tianshan Velvet Cotton" sanitary napkin series and the "Q MO" high-end diaper series, which have maintained strong sales momentum [2] - Despite improvements in tissue gross margins and an increase in the proportion of high-end products, overall gross profit declined due to a drop in sanitary product sales and rising promotional expenses [2]

Core Viewpoint - The company reported a slight decline in revenue and profit for the first half of 2025, but expects steady growth in tissue sales and overall revenue stability due to strategic initiatives in e-commerce and product diversification [1][2] Group 1: Financial Performance - The company achieved revenue of 11.808 billion RMB for the six months ending June 30, 2025, a year-on-year decrease of 0.2% [1] - Profit attributable to equity holders was 1.373 billion RMB, down 2.6% year-on-year, with basic earnings per share at 1.206 RMB [1] - Overall gross profit decreased by approximately 3.2% to about 3.812 billion RMB, with a gross margin of about 32.3%, down from 33.3% in the same period last year [2] Group 2: Market Strategy and Sales Channels - The company benefited from growth in tissue sales and an increase in market share, mitigating the negative impact of intense price competition in the sanitary products industry [1] - E-commerce and new retail sales accounted for approximately 34.4% of total sales, up from 31.8% in the first half of 2024, with sales revenue growing by about 7.9% year-on-year [1] - The company is focusing on diversifying sales channels and enhancing its presence in emerging markets while promoting traditional sales channels [1] Group 3: Product Development and Brand Positioning - The company is actively developing new technologies to enhance product high-end positioning and diversify its product portfolio, responding to increasing consumer demand for personalized and value-added sanitary products [2] - Key high-end products include the "Tianshan Velvet Cotton" sanitary napkin series and the "Q•MO" high-end diaper series, which have maintained strong sales momentum [2] - New product launches, such as the "Cranberry A+" organic cotton sanitary napkin and the "Towards the Wild" high-end tissue series, are expected to improve the sales proportion of high-end products and enhance brand image [2]

Core Viewpoint - The company reported stable revenue performance in the first half of 2025, supported by growth in tissue sales and an increase in market share, despite intense price competition in the sanitary products sector [1] Group 1: Financial Performance - The company's overall revenue slightly decreased by 0.2% year-on-year to approximately RMB 11.808 billion [1] - Overall gross profit fell by about 3.2% to approximately RMB 3.812 billion, with a gross margin declining to around 32.3% [1] - Operating profit decreased by 7.3% to approximately RMB 1.757 billion [1] - Profit attributable to equity holders decreased by approximately 2.6% to around RMB 1.372 billion, with basic earnings per share at RMB 1.206 [1] - The board declared an interim dividend of RMB 0.70 per share [1] Group 2: Sales and Market Strategy - The steady increase in tissue sales is expected to support overall revenue stability in the second half of 2025, driven by multi-channel sales, product personalization, and stable pricing strategies [1] - The company is seizing opportunities in diversified consumer channels, increasing efforts in e-commerce and new retail markets, with e-commerce and new retail sales accounting for approximately 34.4% of total sales, showing a year-on-year growth of about 7.9% [1] - The company continues to promote sales through traditional channels and develop new growth points, with a steady advancement of its multi-channel sales strategy [1] Group 3: Product Development and Brand Enhancement - The company is actively developing new technologies to enhance product high-end features and diversify its product portfolio, responding to the growing demand for personalized and value-added sanitary products [2] - Key high-end products include the "Tianshan Velvet Cotton" sanitary napkin series and the "Q • MO" series of high-end diapers, which have maintained strong sales momentum [2] - New product launches, such as the "Cranberry A+" organic cotton sanitary napkin and the "Towards the Wild" high-end tissue series, are expected to increase the proportion of high-end products in sales and enhance brand image and product reputation [2]

恒安国际(01044)发布公告，该公司将于2025年10月10日派发中期股息每股0.7元人民币。 ...

智通财经APP讯，恒安国际(01044)发布公告，该公司将于2025年10月10日派发中期股息每股0.7元人民 币。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1044） http://www.hengan.com http://www.irasia.com/listco/hk/hengan 網址： 「追求健康，你我一起成長」 | 財務摘要 | | | | | --- | --- | --- | --- | | 二零二五年六月三十日止六個月之中期業績 | | | | | | 未經審核 | | | | 二零二五年 | | 二零二四年 | 變幅 | | 人民幣千元 | | 人民幣千元 | % | | 收入 | 11,808,232 | 11,835,893 | (0.2)% | | 毛利率 | 32.3% | 33.3% | | | 經營利潤 | 1,757,339 | 1,895,891 | (7.3)% | | 公司權益持有人應佔利潤 | 1,372,894 | 1,408,992 | (2.6)% | | 每股收 ...

EF001 免責聲明 | EF001 | | --- | | 其他信息 | | | --- | --- | | 其他信息 | 不適用 | | 發行人董事 | | | | 於本公告刊發日期, 恒安國際集團有限公司董事會成員為: | | 執行董事 | | | 施文博先生 | | | 許清流先生 | | | 許大座先生 | | | 施煌劍先生 | | | 許清池先生 | | | 李偉樑先生 | | | 許文默先生 | | | 獨立非執行董事 | | | 黃英琦女士 | | | 何貴清先生 | | | 保羅希爾先生 | | | 陳闖先生 | | 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 恒安國際集團有限公司 | | 股份代號 | 01044 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 ...

Group 1 - The latest shareholder equity disclosure for Hengan International (01044) and Xinshi Electric Vehicle New Materials (06128) was conducted on August 19, 2025 [1] - Hengan International saw a significant increase in shareholding from 6.60 million shares to 275 million shares, representing a holding percentage increase from 0.57% to 23.71% [1] - Xinshi Electric Vehicle New Materials experienced a decrease in shareholding for both Wu Wenbei and Shen Taoyu, with holdings dropping from 93.50 million shares to 47.50 million shares, resulting in a new holding percentage of 5.06% down from 9.96% [1] Group 2 - The changes in shareholding may be influenced by factors such as rights issues, consolidations, or stock splits, necessitating careful consideration of actual circumstances [1]